Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482916/730-10-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482665/350-30-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482916/730-10-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482517/912-730-25-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481283/985-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_SellingGeneralAndAdministrativeExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement, Allocation Of Net Profits And Losses, Percent

+ References

No definition available.

+ Details

Name:	vrtx_CollaborativeArrangementAllocationOfNetProfitsAndLossesPercent
Namespace Prefix:	vrtx_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Collaborative Arrangement, Allocation Of Research And Development Expenses, Percent

+ References

No definition available.

+ Details

Name:	vrtx_CollaborativeArrangementAllocationOfResearchAndDevelopmentExpensesPercent
Namespace Prefix:	vrtx_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Represents the potential milestone amount to be paid by the entity under the collaboration agreement if drug candidates are approved and commercialized.

+ References

No definition available.

+ Details

Name:	vrtx_CollaborativeArrangementDevelopmentAndRegulatoryPotentialMilestonePaymentsMaximum
Namespace Prefix:	vrtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement, Milestone Payment

+ References

No definition available.

+ Details

Name:	vrtx_CollaborativeArrangementMilestonePayment
Namespace Prefix:	vrtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaborative Arrangement, Right To License, Number Of Targets

+ References

No definition available.

+ Details

Name:	vrtx_CollaborativeArrangementRightToLicenseNumberOfTargets
Namespace Prefix:	vrtx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative Arrangement Up-front License Fee

+ References

No definition available.

+ Details

Name:	vrtx_CollaborativeArrangementUpFrontLicenseFee
Namespace Prefix:	vrtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payment To Acquire Common Stock

+ References

No definition available.

+ Details

Name:	vrtx_PaymentToAcquireCommonStock
Namespace Prefix:	vrtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	dei_LegalEntityAxis=vrtx_CRISPRMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	vrtx_CollaborativeArrangementsByAgreementAxis=vrtx_CRISPRTherapeuticsAGMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	vrtx_CollaborativeArrangementsByAgreementAxis=vrtx_CRISPRJDCAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	vrtx_CollaborativeArrangementsByAgreementAxis=vrtx_CRISPRT1DMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	vrtx_CollaborativeArrangementsByAgreementAxis=vrtx_EntradaTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration, License and Other Arrangements - Additional Information (Details)	1 Months Ended			3 Months Ended		12 Months Ended
	Jan. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Feb. 28, 2023 USD ($)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2019 USD ($) target	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Acquired in-process research and development expenses				$ 76,800,000	$ 347,100,000
Cost of sales				342,600,000	266,900,000
Selling, general and administrative expenses				$ 342,700,000	241,100,000
CRISPR
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, allocation of research and development expenses, percent				40.00%
Allocation of net profits and net losses, percent				40.00%
CRISPR Therapeutics
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, right to exclusively license, number of targets \| target						3
Collaborative arrangement, development and regulatory potential milestone payments maximum						$ 410,000,000
CRISPR JDCA
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment	$ 200,000,000
Allocation of net profits and net losses, percent							60.00%
Cost of sales				$ 15,800,000
Research and development expenses				11,700,000	17,900,000
Selling, general and administrative expenses					$ 5,800,000
CRISPR JDCA \| CRISPR
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Allocation of net profits and net losses, percent							40.00%
CRISPR T1D
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, development and regulatory potential milestone payments maximum		$ 160,000,000
Up-front payment		$ 100,000,000
Entrada Therapeutics
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, development and regulatory potential milestone payments maximum			$ 335,000,000
Milestone payment				$ 75,000,000
Up-front payment			225,100,000
Purchase of common stock			$ 24,900,000